The HMGB2 Knockout A-549 Polyclonal Cells product consists of a heterogeneous population of A-549 human lung adenocarcinoma cells harboring CRISPR/Cas9-mediated disruption of the HMGB2 gene. This polyclonal knockout model provides a robust loss-of-function system for interrogating the diverse biological functions of HMGB2. Unlike clonal isolates, the polyclonal format preserves population-level heterogeneity, mitigating clonal artifacts and enabling more physiologically relevant studies. The gene disruption is achieved through CRISPR/Cas9-targeted editing, resulting in a functional knockout suitable for examining HMGB2-dependent processes in a cancer-relevant context.
The A-549 host cell line, derived from a human lung adenocarcinoma, is a widely utilized epithelial model in non-small cell lung cancer (NSCLC) research. These adherent cells exhibit characteristic hallmarks of lung carcinoma, including aberrant proliferative signaling, altered DNA damage responses, and dysregulated inflammatory pathways. A-549 cells are extensively employed in drug screening assays, migration and invasion studies, and investigations of oncogenic signal transduction, making them an ideal background for dissecting the contributions of HMGB2 to lung cancer biology.
HMGB2 encodes a highly conserved non-histone chromosomal protein that functions as both a nuclear DNA chaperone and an extracellular damage-associated molecular pattern (DAMP). In the nucleus, HMGB2 binds and bends DNA, facilitating transcription, DNA repair, and recombination by interacting with factors such as histone H1, p53, and other chromatin-associated proteins. Following cellular stress or necrosis, HMGB2 is released extracellularly, where it engages pattern recognition receptors including RAGE, TLR2, and TLR4 to propagate inflammatory signaling. Downstream of receptor activation, HMGB2 mobilizes adaptor proteins MyD88, IRAK1, and TRAF6, ultimately activating NF-??B and MAPK (ERK, p38) cascades, which drive expression of pro-inflammatory cytokines such as TNF-?? and IL-6. Upstream regulators of HMGB2 expression and release include TNF-??, IL-1??, hypoxia, oxidative stress, and DNA-damaging agents, placing HMGB2 at the intersection of genotoxic and inflammatory responses.
In the context of A-549 cells, HMGB2 knockout is predicted to impair both nuclear and extracellular functions. Loss of nuclear HMGB2 compromises DNA repair efficiency and transcriptional reprogramming in response to genotoxic insults, which may sensitize these cells to DNA-damaging chemotherapeutics. Concurrently, disruption of extracellular HMGB2-mediated signaling attenuates autocrine and paracrine inflammatory loops through RAGE and TLRs, potentially reducing NF-??B-driven cytokine production and dampening tumor-promoting inflammation. The polyclonal knockout population thus serves as a powerful tool for dissecting the dual roles of HMGB2 in DNA damage repair and inflammation within the same NSCLC model, offering insights into mechanisms of drug resistance and metastatic progression.
This product is optimized for a range of experimental applications, including functional genomics, drug discovery, and cancer biology research. Typical assays enabled by these cells include western blotting and RT-qPCR to confirm HMGB2 knockdown, MTT and Annexin V assays for proliferation and apoptosis profiling, transwell migration and invasion assays to interrogate metastatic behavior, and NF-??B luciferase reporter or ELISA-based quantification of downstream cytokine secretion (e.g., IL-6, TNF-??). Immunofluorescence can be employed to examine HMGB2 subcellular localization and its absence in knockout cells. These applications make the HMGB2 Knockout A-549 Polyclonal Cells particularly valuable for studying NSCLC pathogenesis, DNA repair dynamics, inflammatory signal transduction, and therapeutic response. For additional details or custom requests, please contact Ascent Research.
